The impact of insole wedge height on knee alignment, joint space width, and patient-reported outcomes in medial knee OA Authors: Bashar Al Qaroot, Mohammad Sobuh, Mohammad Hamdan, Jihad Al Ajlouni, Farah Al-Imyan, Eman Al-Laham, Ibrahim Altubasi, Aws Khanfar, Osama Farouk, Osama Farouk, Rohan Kothurkar, Rohan Kothurkar, Rohan Kothurkar Published: 2026 ABSTRACT IntroductionLateral wedge insoles (LWIs) are a recommended conservative treatment for medial knee osteoarthritis (OA), yet the optimal wedge height remains unclear. This randomized controlled trial evaluated the effects of different LWI heights on radiographic outcomes in patients with medial knee OA.MethodsThis study employed a randomized, controlled, parallel-arm design with a sequential, within-subject dose-escalation intervention arm. Thirty-four participants with mild-to-moderate medial knee OA (Kellgren- Lawrence grade <3) were randomized into a case group (n = 17) receiving custom LWIs (4 mm, 8 mm,12 mm, 16 mm) and a control group (n = 17) receiving standard care. Radiographic assessments (femorotibial angle [FTA], medial joint space width [MJSW]) and patient-reported outcomes (WOMAC) were performed at baseline and follow-up. Mixed ANOVA analyzed group and time effects.ResultsThe 12 mm LWI significantly reduced varus alignment (FTA: 177.3° ± 2.8 vs. 178.1° ± 2.7 with 4 mm, p < 0.05) in the non-dominant limb. No significant FTA change was observed in the dominant limb, suggesting that limb-specific loading history may modulate biomechanical responsiveness to orthotic correction. No significant FTA changes occurred in the dominant limb. MJSW remained stable in the case group but narrowed in controls (3.04 ± 0.7 mm vs. 3.16 ± 0.8 mm, p < 0.05). The 16 mm LWI was discontinued due to poor tolerability (11/17 participants). The LWI group also showed significant improvements in WOMAC total and pain scores compared to controls.ConclusionAmong the clinically tolerable LWI heights tested, the 12 mm wedge provided the best balance between biomechanical efficacy and patient tolerability. It significantly improved varus alignment (in the non-dominant limb), halted joint space narrowing, and reduced pain and overall symptoms. The 16 mm wedge was poorly tolerated (11/17 participants) and was therefore deemed clinically impractical. Future studies should explore personalized height selection and long-term outcomes. Introduction Osteoarthritis (OA), a leading cause of pain and functional disability, is the most common musculoskeletal condition worldwide [1]. It affects weight-bearing joints, particularly the knee joint. The prevalence of knee OA increases with age, with females being more susceptible. In particular, ~ 13% of women and ~10% of men who are over 60 years old have symptomatic knee OA [2,3]. This is expected to further increase especially in developing countries where access to surgical intervention might not be readily available [4,5]. The etiology of knee OA remains unknown [6,7]. However, an interaction between systemic and biomechanical factors can contribute to its development and progression [3,8]. These factors include, but not limited to, obesity, previous knee injury or surgery, genetic susceptibility and knee malalignment [3]. In general, knee OA could develop in one or more of the three different knee compartments; medial tibiofemoral, lateral tibiofemoral and/or patellofemoral [9], of which, the medial tibiofemoral compartment is the most common [2,10]. This is due to the uneven load distribution during normal gait, as most of the total body’s load (60–80%) is transmitted through the medial side of the knee joint [2]. This uneven load distribution results in medially acting ground reaction force at the knee joint during the stance phase of gait. As a result, external knee adduction moment is generated. Thus, in relation to the femur, the tibia will rotate medially into a varus position [11]. This position is believed to be responsible for osteoarthritic changes in the medial knee compartment [12]. These changes are characterized by damaging the entire joint structure in an irreversible manner [2]. Including, articular cartilage degeneration, articular capsule stretching, synovitis, subchondral bone sclerosis, periarticular muscles weakness and ligaments laxity [9–11]. Consequently, restrictions of patients’ ability to perform daily activities due to knee pain, stiffness, joint effusion and limitation of knee range of motion [1,12,13]. Recommended treatment for medial knee OA varies depending on the severity of OA and its effects on the patient [13,14]. Severe cases may require an operative treatment. Whereas, mild to moderate cases could be managed with one or more of the non-operative treatment modalities, including activity modification, physical therapy, pharmaceutical (drugs or injections) and joint unloading therapy through orthotic intervention [14–16]. The aims of the non-operative treatment are predominantly to relieve the pain, improve the function and inhibit disease progression [14]. Joint unloading therapy by a lateral wedge insole (LWI) is one of the first-line modalities in the non-operative treatment of symptomatic knee OA [4]. It is a simple, safe and low-cost option that has been recommended in 12 of the 13 existing guidelines for the management of medial knee OA [17]. The goal of using a LWI is to increase foot pronation in order to centrally-realign the position of the ground reaction force vector relative to the knee joint during weight-bearing activities. This would reduce the loading at the medial knee compartment and consequently would mitigate knee pain and possibly cease OA progression [13,14]. Some published investigations indicated that the higher the LWI, the better the knee OA control [13,18]. However, the appropriate LWI height has, to the best of our knowledge, been never investigated. Therefore, the aim of this randomized control trial (RCT) is to investigate LWI effectiveness in knee OA management and to identify the best height for knee OA management based on radiographic evaluation. Method The study was ethically approved by the institutional committee for research review at the University of Jordan hospital, Amman, Jordan (208/2020). This study employed a combined design to address both the natural history of medial knee OA and the dose-response effects of LWIs. It consisted of two randomly assigned groups (control and case) with a repeated-measures structure. Participants in the control group were assessed at baseline and then at four consecutive follow-up visits (at 4-week intervals) without any orthotic intervention, to track disease progression. Participants in the case group were assessed at baseline and then after sequential 4-week periods of wearing 4 mm, 8 mm, 12 mm, and 16 mm LWIs. Thus, the ‘time’ factor in the analysis represents chronological follow-up for the control group and incremental intervention dose for the case group (see Fig 1). Overview of the flow of the investigation. LWI: lateral wedge insole. WOMAC: Western Ontario and McMaster Universities osteoarthritis index. The intervals between successive assessments was 4 weeks. In the case group, the interval between casting and delivering the 4 mm LWI was one week. Participant selection Participant recruitment took place at the University of Jordan Hospital’s orthopedic clinic. While all participants were recruited between September 1, 2020, and August 11, 2021, follow-up efforts continued until the final visit was completed on March 1, 2024. The extended timeline resulted from a concerted effort to retain and complete the protocol with a single non-adherent participant. Because enrollment was confined to the original one-year approval period, no ethical extension was needed. Eligibility required a clinical and radiographic diagnosis of bilateral mild knee osteoarthritis according to the American College of Rheumatology clinical criteria, with Kellgren-Lawrence grade < 3 [19]. Additionally, participants had to report persistent walking pain exceeding 3/10 on a numerical rating scale. Severe cases were excluded based on evidence suggesting that LWI demonstrate optimal efficacy in mild/moderate stages, ensuring the study population represented those most likely to benefit from LWI intervention [20]. Exclusion criteria included previous lower limb fracture or trauma, ankle or foot arthrodesis, musculoskeletal problems, currently using an orthosis or an ambulation aid to walk. Participants who fell within inclusion criteria were given a detailed participant information sheet. Potential participants who showed willingness to participate in the study contacted the chef investigator and were then asked to sign an informed consent form. Limb dominance was determined for each participant at the time of enrollment through self-report, by asking which leg they would favorably use to kick a ball. Table 1 shows participant’s information. 10.1371/journal.pone.0354335.t001Table 1Subject’s characteristics information. Where applicable, data presented as mean ± standard deviation.CharacteristicControl Group (n = 17)Case Group (n = 17)p-valueAge, years60.9 ± 9.859.9 ± 9.50.749Body Mass Index (kg/m²)29.8 ± 4.231.9 ± 5.60.207Weight (kg)78.2 ± 11.785.4 ± 20.90.204Height (m)162.1 ± 4.2162.9 ± 11.20.784Gender, n0.500Male34Female1413Dominant Side, n1.000Right (R)1716Left (L)01 Subject’s characteristics information. Where applicable, data presented as mean ± standard deviation. LWI The LWI were custom-made from a cast impression of each participant’s feet in the case group. The LWI was made of two glued parts (the insole and the lateral wedge). The insole covered the full length of the foot with medial arch support and was made from 2 mm Thermolyn Trolen (PE-LD). The lateral wedge was made from a black Neoprene rubber with different thicknesses (i.e., 4 mm, 8 mm, 12 mm and 16 mm thickness, as measured from the lateral side). The LWI was tapered laterally to align with the level of the medial side of the foot. Each lateral wedge thickness was glued to the inferior surface of the insole, and after each assessment, was unglued and changed with another thickness (Fig 2). The lateral wedge insole. A) lateral view and B) frontal view. The insole in white and the lateral wedge in black. Radiographic imaging To assess knee OA in both control and case groups, short AP weight-bearing X-ray radiographs of both knees (knees extended and heels together) were acquired. Short, weight-bearing knee radiographs were selected as they are a validated and commonly used modality for assessing femorotibial alignment and medial joint space width in conservative knee OA trials, while minimizing radiation exposure and reflecting routine clinical practice [21,22]. All images were acquired with an X-ray beam (63 KV, 6.3 mAs), a focus of 0.5 mm and a focus to film distance of 115 cm. These images were used to measure the femorotibial angle (FTA) and the medial joint space width (MJSW) using the synapse software system (Version 4.4, Fujifilm, Japan). The FTA was measured from the intersection of the femoral and the tibial anatomical axes. The femoral and tibial axes were drawn similarly by connecting the mid-points of the proximal and the distal respective shafts [21] (Fig 3.A). The resulting angle represents the relative alignment of the knee joint (measured from the lateral side), where a reduction in the FTA is considered as improvement in joint alignment in medial knee OA patients [21]. Radiographic Knee Metrics. A. Measurement of the femorotibial angle (FTA): The double arrows indicate the proximal and distal widths of the femoral and tibial shafts, respectively. Midpoints of these widths were connected to define the anatomical axes of each bone. The angle formed at the intersection of these axes represents the FTA. B. Measurement of the medial joint space width (MJSW): Dashed lines represent tangents to the femoral condyles and tibial plateaus. The solid horizontal line indicates the total width of the proximal tibia and was used to identify a point located 20% from the medial edge (marked by a double arrow). The MJSW was measured at this point as the perpendicular distance between the dashed lines, shown as a solid vertical line marked by an arrow. Regarding the MJSW, it was measured as the distance between two lines tangent to both the femoral condyles and the tibial plateaus at a point 20% from the medial tibial plateau (Fig 3.B) [22]. An increase in the distance is considered as improvement in joint width in medial knee OA patients. Patient reported outcomes In addition to radiographic measures, patient-reported outcomes were assessed at each visit using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). The WOMAC is a validated, self-administered questionnaire that evaluates three domains: Pain (5 items), Stiffness (2 items), and Physical Function (17 items). Each item is scored on a Likert scale, with higher scores indicating worse pain, stiffness, and functional limitations. The total WOMAC score and individual sub-scores were calculated for each participant at every assessment time point. Assessment: Case group Each participant in the case group was assessed five times: a baseline assessment without LWI and four other assessments while wearing LWIs of 4 mm, 8 mm, 12 mm, and 16 mm thickness, respectively. The interval between assessments was set at four weeks, which was considered sufficient to detect alterations in medial knee OA patients following LWI use [18,19,21–23]. This interval was also chosen to minimize the potential of participant dropout (due to the length of the study), ensure compliance, reduce the burden of long follow-up periods, and mitigate potential confounding factors such as adaptation effects or changes in symptoms unrelated to the intervention. Assessment: Control group Each participant in the control group was assessed five times at four-week intervals, without LWI, to match the assessment schedule of the case group. Results A total number of 44 bilateral medial knee OA participants were recruited. Of those, 10 participants withdrew from the study due to different reasons; including, coronavirus pandemic, discomfort while wearing the first given LWI, transportation difficulties and some of them dropped out of the study for no explained reasons. The remaining 34 participants were randomly divided using a dynamic, sequential randomization approach where each participant’s group allocation was determined at the time of enrollment using a computerized random number generator. This real-time allocation strategy was developed to accommodate our study’s practical constraints; specifically, the inability to predict final enrollment numbers at the study’s onset. The system automatically maintained balanced group sizes throughout the recruitment period. Importantly, this approach reflected clinical situation, where participants present randomly, while still maintaining the scientific integrity of randomized assignment. Based on randomization, 17 participants were allocated to the case group (59.9 ± 9.5 years old) who have received the LWIs and 17 participants were allocated to the control group (60.9 ± 9.8 years old) with no orthotic intervention. Participants in both groups were blinded about the presence of the other group. Of the 17 participants in the case group, 11 were unable to wear the 16 mm LWI due to pain and discomfort and were withdrawn from this condition. The remaining 6 participants completed the 16 mm condition. Due to the high dropout rate (64.7%), the 16 mm data were excluded from the primary analysis because the reduced sample size (n = 6) would have compromised statistical power and introduced significant selection bias. However, an exploratory analysis of the 6 completers is provided as supplementary material (see S1 File). Exploratory analysis of the 16 mm completers (n = 6) revealed a non-significant trend toward further FTA improvement compared to 12 mm (mean difference = −0.6°, p = 0.18). Due to the small sample size and potential selection bias, these findings should be interpreted with caution and are provided in supplementary material (S1 File). Statistical analysis Mixed ANOVA was performed to analyze the effects of group and different LWI heights on WOMAC scores, FTA, and MJSW. In this model, the ‘time’ factor represents the chronological follow-up visits for the control group and the incremental wedge-height condition for the case group. Consequently, the group×time interaction was specifically interpreted as a test of whether the dose-response trajectory in the case group differed significantly from the natural progression trajectory in the control group. Since a total number of 34 participants completed the study from the original 44 recruits, it should be noted that the final sample size may have limited the statistical power to detect smaller effect sizes, particularly in the side-specific analyses. Baseline characteristics between the control and case groups were compared using independent samples t-tests for continuous variables and a Chi-square test/Fisher’s exact test for categorical variables (gender and side dominance, respectively) Post-hoc power analysis Post-hoc power analyses were performed for the primary outcomes (FTA and MJSW) and WOMAC subscales based on the observed effect sizes (partial η²) from the Mixed ANOVA, with α = 0.05 and the achieved sample size (n = 34). As shown in Table 2, adequate power (0.82) was observed for the significant FTA interaction on the left side. However, power was low for the right side FTA (0.06), right side MJSW (0.15), and WOMAC stiffness (0.32) and physical function (0.42) subscales. Thus, null findings for these outcomes should be interpreted with caution. 10.1371/journal.pone.0354335.t002Table 2Post-hoc power analysis for primary and secondary outcomes based on observed effect sizes (partial η²) from Mixed ANOVA (α = 0.05, n = 34).OutcomeEffect Size (partial η²)Observed PowerFTA (left side) – group×time interaction0.0530.82FTA (right side) – group×time interaction0.0010.06MJSW (left side) – group×time interaction0.0320.61MJSW (right side) – group×time interaction0.0090.15WOMAC Stiffness – group×time interaction0.0150.32WOMAC Physical Function – group×time interaction0.0200.42 Post-hoc power analysis for primary and secondary outcomes based on observed effect sizes (partial η²) from Mixed ANOVA (α = 0.05, n = 34). Patient reported outcomes (WOMAC) Regarding the total WOMAC score, Mauchly’s test of sphericity was not significant, therefore sphericity assumption was met. A significant interaction effect (group*time) was found (F (3,93) = 2.84, p = 0.042). Post-hoc analysis revealed that while the control group showed no significant change at any time point, the case group demonstrated a significant decline (improvement) in the total score. Specifically, the case group’s scores at the 3rd (8 mm LWI) and 4th (12 mm LWI) time points were significantly lower than at baseline (p = 0.030 and p = 0.002, respectively) (Fig 4). Changes in WOMAC total and sub scores. Changes in WOMAC total and stiffness, pain, and physical function sub-scores across conditions without and with 4 mm, 8 mm, and 12 mm lateral wedge insoles (LWI). The solid line represents the case group, while the dashed line represents the control group. The higher the score, the worse the condition is. Regarding WOMAC pain sub-score, Mauchly’s test of sphericity was not significant, therefore sphericity assumption was met. A significant interaction effect (group*time) was found (F (3,93) = 3.92, p = 0.011). The case group reported significant reductions in pain at the 2nd (4 mm LWI), 3rd (8 mm LWI), and 4th (12 mm LWI) visits compared to baseline (all p < 0.05). No significant changes were observed in the control group (Fig 4). Regarding WOMAC stiffness and physical function sub-scores, Mauchly’s test of sphericity was significant, therefore sphericity assumption was not met, and Greenhouse-Geisser test was used. There were no significant interaction effects for the stiffness (p = 0.553) or physical function (p = 0.098) sub-scores. However, a significant main effect of time was observed for physical function (p = 0.03), with follow-up tests indicating a significant improvement in the case group at the 4th time point (12 mm LWI) compared to baseline (p = 0.045) (Fig 4). The absence of significant interaction effects for the stiffness and physical function subscales should be interpreted cautiously, as post-hoc power analysis indicated insufficient power (observed power = 0.32 and 0.42, respectively) to detect small-to-moderate effect sizes. The significant main effect of time for physical function suggests a potential treatment benefit, but this finding requires confirmation in larger samples. FTA On the right side, Mauchly’s test of sphericity was not significant, thus, sphericity assumption was met. The results indicate no significant interaction effect (group×time) on the FTA (F (3,90) = 0.027, p = 0.994). Also, no significant group nor time effects (F (1,30) = 0.055, p = 0.816) and (F (3,90) = 0.267 p = 0.849), respectively. On the left side, Mauchly’s test of sphericity was significant, thus, sphericity assumption was not met. Accordingly, Greenhouse-Giesser test was used for further analysis. The results indicate a significant interaction effect (group×time) (F (3,93) = 5.231, p = 0.005). Particularly, for the control group there was no significant change among different conditions. However, for the case group, there was a significant decrease with 12 mm LWI (177.3 ± 2.8) compared to the 4 mm LWI (178.1 ± 2.7) (Fig 5). Knee Metrics Across LWI Conditions. Mean femorotibial angle (FTA) and medial joint space width (MJSW) of the right and left knees across conditions without and with 4 mm, 8 mm, and 12 mm lateral wedge insoles (LWI). Error bars represent standard deviations. The solid line is the case group and the dashed line is the control group. Notably, this significant FTA improvement was observed exclusively on the left side, which was the non-dominant limb in the majority (16/17) of participants. No significant FTA changes were detected on the right (dominant) side in either group. MJSW On the right side, Mauchly’s test of sphericity was significant, thus, sphericity assumption was not met. Accordingly, Greenhouse-Giesser test was used for further analysis. The results indicate no significant interaction effect (group*time) (F (3,90) = 0.883, p = 0.419). Also, there was no significant group nor time effects (F (1,30) <.001, p = 0.993) and (F (3,90) = 1.563 p = 0.204) respectively. On the left side, Mauchly’s test of sphericity was not significant, thus, sphericity assumption was met. The results indicate a significant interaction effect (group*time) (F (3,93) = 3.036, p = 0.033). For the case group, there was no significant change among different time points. However, for the control group there was a significant decrease in the third visit (3.04 ± 0.7) compared to the first baseline visit (3.16 ± 0.8) (Fig 5). Discussion The current investigation shows that MJSW reduced in the control group (both right and left sides) over successive visits where it was statistically significant in the 3rd visit for the left side (3.04 ± 0.7). This aligns with previous studies that reported deterioration and joint space narrowing, in knee OA, without intervention [24]. In contrast, MJSW remained unchanged in the case group, indicating that the LWI may have helped in preventing joint narrowing and thus decelerating joint degeneration [24]. However, the 4-week intervention period does not establish whether this structural preservation translates into sustained clinical benefit or delayed disease progression beyond the intervention period. Longer-term follow-up studies (e.g., 12 months) are needed to confirm the durability of these effects. In accordance with previous studies that showed reduced varus alignment in knee OA patients wearing LWI [24–26], the current study revealed a reduction in varus knee angle as identified by the FTA whilst wearing 4 mm, 8 mm, and 12 mm LWIs. This reduction was statistically significant when a 12 mm LWI was worn on the left side (177.3 ± 2.8), suggesting that the higher the LWI, the more effective it is as long as it remains pain-free. Since the LWIs corrects knee alignment, it may reduce biomechanical stress on the medial knee compartment, potentially slowing the progression of OA [27]. Additionally, this realignment could lower the external knee adduction moment (EKAM) by redistributing joint forces more evenly [27]. While full-length lower-limb imaging provides comprehensive assessment of the mechanical axis, the present study was designed to evaluate knee-level structural changes relevant to conservative orthotic management rather than global limb deformity. Both the slight increase in FTA and reduction in MJSW in the control group demonstrated progressive varus malalignment (Table 3) and OA deterioration compared to the case group, providing further evidence for the therapeutic value of LWI in managing medial knee OA progression. 10.1371/journal.pone.0354335.t003Table 3Femorotibial angle (FTA, degrees) and medial joint space width (MJSW, mm) measurements at baseline and follow-up visits for control and case groups (4 mm, 8 mm, and 12 mm LWIs). Values represent mean (SD) for right and left knees. LWI: lateral wedge insole.GroupVisit / InterventionRight KneeLeft Knee FTA Control 1st Visit (Baseline)177.12 ± 3.68178.17 ± 2.962nd Visit177.11 ± 3.42178.11 ± 2.973rd Visit177.00 ± 3.60178.23 ± 2.904th Visit177.00 ± 3.64178.58 ± 2.76 Case Baseline (No LWI)177.47 ± 2.96178.00 ± 2.714mm LWI177.47 ± 3.08178.00 ± 2.638mm LWI177.31 ± 3.28177.56 ± 2.6512mm LWI177.41 ± 3.04177.29 ± 2.75 MJSW Control 1st Visit (Baseline)3.70 ± 1.013.16 ± 0.792nd Visit3.57 ± 1.003.16 ± 0.803rd Visit3.44 ± 0.913.04 ± 0.664th Visit3.53 ± 1.003.09 ± 0.70 Case Baseline (No LWI)3.70 ± 0.993.52 ± 0.964mm LWI3.61 ± 0.883.51 ± 1.008mm LWI3.62 ± 0.983.53 ± 1.0412mm LWI3.66 ± 0.933.56 ± 0.99 Femorotibial angle (FTA, degrees) and medial joint space width (MJSW, mm) measurements at baseline and follow-up visits for control and case groups (4 mm, 8 mm, and 12 mm LWIs). Values represent mean (SD) for right and left knees. LWI: lateral wedge insole. Current findings offer preliminary guidance for identifying an optimal LWI height to enhance treatment efficacy (i.e., 12 mm LWI). This structural improvement was paralleled by significant patient-reported benefits, as evidenced by the reduction in total WOMAC score and pain at the 12 mm LWI condition. The clinical significance of these findings is best appreciated by integrating the radiographic and patient-reported outcomes, as visualized in Fig 6. This Fig illustrates the direct relationship between the structural improvement in joint space and the concurrent reduction in patient-reported pain, closing the loop between laboratory data and tangible clinical benefit. Visualizing the pathway from structural improvement to symptomatic benefit. The bars demonstrating the increase in medial joint space width (MJSW) from baseline to the 12 mm lateral wedge insole (LWI) condition in the case group (left knee), indicating structural improvement. Corresponding line graph showing the progressive reduction in WOMAC Pain scores across the intervention period, demonstrating concurrent symptomatic relief. Together, these panels form a clinical argumentation loop, linking objective biomechanical data to tangible patient benefit. The 16 mm LWI could not be adequately tested due to poor tolerability, with 11 of 17 participants discontinuing this condition. While an exploratory analysis of the 6 completers suggested a possible trend toward greater biomechanical correction, the high dropout rate precludes any definitive conclusion about the efficacy of the 16 mm height. Critically, this high dropout rate is itself a clinically significant finding: it demonstrates that the 16 mm wedge, regardless of its theoretical biomechanical potential, is impractical for routine clinical use due to discomfort. This discomfort is possibly associated with asymmetric muscles activation and the body’s adaptive challenges to the more pronounced foot position adjustment [26,28]. This highlights a critical clinical consideration for LWI prescription in which the therapeutic height must balance biomechanical efficacy with wearability. While higher LWI may offer greater advantages, the optimal height represents a compromise between therapeutic benefit and practical tolerability, as clinical effectiveness ultimately depends on use. Thus, the 12 mm wedge represents the optimal balance between biomechanical efficacy and clinical feasibility among the heights tested. FTA reduction was statistically significant only on the left (non-dominant) side. The majority of participants (16/17) were right-leg dominant. This side-specific effect could hypothetically reflect differential biomechanical responsiveness rather than a failure of the intervention. Limb dominance is associated with asymmetric loading history, with the dominant limb experiencing higher cumulative impact forces and propulsive demands during gait [29]. This chronic, elevated mechanical stress may lead to subtle but functionally significant adaptations in cartilage composition, subchondral bone stiffness, and periarticular soft tissues. These adaptations could render the dominant joint less responsive to acute biomechanical correction, inhibiting the kinematic chain effect of foot pronation before producing a measurable FTA shift within the 4-week intervention period. Importantly, this interpretation is supported by the absence of side-specific differences in patient-reported outcomes (WOMAC) and MJSW preservation, which were observed bilaterally. Thus, the absent FTA effect on the dominant side does not indicate that the LWI is ineffective, but rather that limb dominance is a clinically relevant factor modulating biomechanical responsiveness. This finding does not undermine the overall therapeutic benefit of the 12 mm LWI, which is supported by convergent evidence from patient-reported outcomes and joint space preservation. Additionally, post-hoc power analysis revealed low statistical power (0.06) for this comparison, suggesting the null finding on the dominant side may also be partially attributable to insufficient sample size. Lastly, while previous studies support using higher lateral wedge insole (LWI) heights for knee symptom relief [13,30–32], their methodology had key limitations. These studies tested only one wedge height per patient, making it impossible to determine if another height might work better for that individual. Results could reflect patient-specific factors rather than true treatment effects. Additionally, adjustments were permitted during trials [30], and inconsistent insole materials [30] may have biased outcomes. In contrast, our study directly compared multiple LWI heights on same participants under standardized conditions, eliminating these confounding factors. Furthermore, beyond symptomatic relief, our study provides preliminary evidence of potential disease-modifying effects. While most previous LWI trials focused on pain reduction or biomechanical parameters such as the external knee adduction moment (EKAM) [24,27,28], our radiographic findings demonstrate stabilization of MJSW in the case group compared to progressive narrowing in controls. This suggests that LWIs may decelerate joint space narrowing (a key structural marker of OA progression) within a relatively short intervention period. To our knowledge, this is among the first studies to demonstrate both dose-dependent biomechanical improvement and structural preservation concurrently, while also systematically documenting tolerability across multiple heights. This combination of findings provides a more comprehensive evidence base for clinical prescription practice. Limitation This study has several limitations that should be considered when interpreting the results. First, the final sample size (n = 34), while sufficient to detect the primary effects, limited statistical power for side-specific and subgroup analyses. Post-hoc power analysis revealed low power for the dominant-side FTA (0.06) and WOMAC stiffness/physical function subscales (0.32–0.42); thus, these null findings may reflect insufficient power rather than a true absence of effect. Second, while baseline demographics were well-balanced, we did not systematically control for potential confounders such as disease duration, physical activity level, occupational demands, comorbidities, or medication dosage/frequency, all of which may influence disease progression and treatment response. Third, the sequential administration of different wedge heights within the case group partially confounds the ‘time’ factor with intervention dose. Consequently, the group×time interaction compares the dose-response trajectory against natural progression, rather than a pure chronological treatment effect. Fourth, the FTA improvement was observed only in the non-dominant limb, limiting the generalizability of this structural finding; this may reflect differential loading history or insufficient power on the dominant side. Fifth, the 16 mm condition was excluded from primary analysis due to a 64.7% dropout rate, and the small number of completers (n = 6) precludes definitive conclusions about its efficacy. Thus, our conclusion regarding 12 mm efficacy is limited to the clinically tolerable range of heights tested. Finally, the 4-week follow-up period, while sufficient to detect acute changes, does not establish the long-term sustainability of these effects. Extended follow-up studies are needed to determine whether the observed MJSW stabilization translates into delayed disease progression and sustained clinical benefit. Additionally, while WOMAC provides validated patient-reported outcomes, we did not include objective functional measures (e.g., gait analysis, timed walk tests), which should be incorporated in future studies. Assessment of global mechanical axis alignment using full-length lower-limb imaging was also beyond the scope of this study. Conclusion This study provides valuable insights into the dose-response relationship of LWIs in managing medial knee OA. Among the clinically tolerable heights tested, the 12 mm LWI offered the best balance between biomechanical efficacy and patient tolerability, significantly improving varus alignment (in the non-dominant limb), halting joint space narrowing, and reducing pain and symptoms. The 16 mm LWI, while potentially more effective biomechanically, was poorly tolerated by the majority of participants and is therefore clinically impractical. These findings support the use of 12 mm LWIs as a conservative management strategy and highlight the need for personalized height selection based on individual tolerability. The varus-correcting effect of the 12 mm LWI was observed exclusively in the non-dominant limb, suggesting that limb-specific loading history may modulate biomechanical responsiveness to orthotic correction. This observation does not undermine the overall therapeutic benefit of the intervention, as symptom improvement and joint space preservation were observed bilaterally. However, it highlights the complex interplay between joint loading, limb dominance, and OA progression—an area that warrants further investigation in future trials designed to account for limb dominance as a stratification variable. This study contributes to the growing body of evidence supporting conservative management of knee OA, offering a simple and low cost strategy. Future research should explore long-term outcomes (e.g., 12-month follow-up) to determine whether the observed structural preservation translates into sustained clinical benefit and delayed disease progression. Additionally, studies investigating individual biomechanical factors, patient tolerance, long-term adherence, dynamic gait changes, and the potential for combining LWIs with other therapies are needed to optimize personalized treatment decision. These findings should be interpreted within the context of knee-level assessment and short-term conservative management rather than whole-limb deformity correction. Supporting information Supporting information file. (XLSX) Transfer Alert This paper was transferred from another journal. As a result, its full editorial history (including decision letters, peer reviews and author responses) may not be present. 31 Aug 2025 3 Nov 2025 Dear Dr. Al Qaroot, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Dec 18 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. We look forward to receiving your revised manuscript. Kind regards, Osama Farouk Academic Editor PLOS ONE Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf 2. Please provide a complete Data Availability Statement in the submission form, ensuring you include all necessary access information or a reason for why you are unable to make your data freely accessible. If your research concerns only data provided within your submission, please write "All data are in the manuscript and/or supporting information files" as your Data Availability Statement. 3. Please amend your manuscript to include your abstract after the title page. 4. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? Reviewer #1: Partly Reviewer #2: Yes ********** 2. Has the statistical analysis been performed appropriately and rigorously? -->?> Reviewer #1: Yes Reviewer #2: No ********** 3. Have the authors made all data underlying the findings in their manuscript fully available??> The PLOS Data policy Reviewer #1: No Reviewer #2: Yes ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English??> Reviewer #1: Yes Reviewer #2: Yes ********** Reviewer #1: Key questions for the authors include: Why were patient-reported outcomes (e.g., pain, function) not included, as these are critical for clinical relevance? Given the small final sample and inconsistent side-specific results, is the study sufficiently powered? The post-hoc explanation for limb dominance effects is speculative without pre-study limb assessment, Suggest providing more pre evaluation data. Reviewer #2: Starting from the phenomenon of “increased hip replacement rates in dominant limbs,” we can infer that “mechanical stress” may be the core influencing mechanism. Concurrently, confounding factors such as occupation and BMI cannot be overlooked. Ultimately, this leads to the specific application of the “LWI (lateral wedge insole) study,” forming a complete logical chain of “phenomenon - mechanism - application.” However, the current argument has several critical shortcomings that require refinement: 1. Unclear mechanism explanation: The specific pathway by which “increased mechanical stress on the dominant side compromises BMI effectiveness” remains undefined. The impact of mechanical stress on BMI's protective role could either directly negate its benefits or indirectly interfere through mediating factors like joint load distribution or local tissue metabolism. This key mechanism remains unclear and warrants further exploration. 2. Missing contextual basis: When mentioning that “LWI effects were not observed on the right side,” the paper fails to provide the widely accepted supporting rationale. Most individuals exhibit physiological characteristics of right-handedness/right-footedness, which may lead to higher frequency and greater load on the right limbs during daily activities. This could consequently affect the intervention efficacy of LWI. The omission of this contextual information may leave non-specialist readers with a somewhat unclear understanding of the “right-side specificity.” Table Optimization Directions 1. Table 1 Improvement: Adopt the three-line table format mandated by clinical research standards, clearly distinguishing headers, data columns, and footers. Additionally, incorporate gender and age as critical confounding factors during data analysis. Employ stratified analysis and multivariate regression to eliminate their interference, ensuring result accuracy. 2. Table 2 Improvement: Similarly, adhere to the three-line table format and supplement with tests or adjustments for baseline characteristic balance (e.g., gender, age). If other potential confounders exist (e.g., disease duration, comorbidities), incorporate them into the control scope to avoid compromising the reliability of conclusions. Enhancing the Clinical Argumentation Loop The logical framework of clinical research must form a complete loop: “Data Support → Clinical Validation → Patient Benefit.” “Clinical image comparisons” serve as the core bridge linking ‘data’ to “patient benefit.” The original text only addresses “multi-height data comparisons under standardized conditions,” achieving laboratory-level variable control but failing to provide critical clinical support through actual images: • Supplement with pre- and post-intervention joint imaging (e.g., X-ray, MRI) to visually demonstrate structural benefits like joint space widening and osteophyte reduction. • Incorporate functional assessment images (e.g., gait analysis diagrams, pain VAS trend charts) to demonstrate how data differences translate into tangible clinical outcomes like “reduced joint pain” and “enhanced walking ability.” Without such visual validation, the conclusion that “LWI studies show superiority” lacks the critical link between laboratory data and real patient benefits, failing to form a complete clinical evidence loop. ********** what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy Reviewer #1: Yes: Chunlin Yang Reviewer #2: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation. NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications. Submitted filename: review comments.docx 13 Nov 2025 Comment Response Reviewer 1 Why were patient-reported outcomes (PROs) not included? We thank the reviewer for this critical and insightful comment. We completely agree that patient-reported outcomes (PROs) are essential for evaluating the clinical relevance of interventions for knee OA. In our initial submission, we focused exclusively on the radiographic outcomes (FTA and MJSW) to maintain a clear and concise narrative on the structural and biomechanical effects of different LWI heights. However, we did indeed collect PROs throughout the study using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). In direct response to the reviewer's comment, we have now integrated the full WOMAC results into the manuscript. The data show significant and clinically meaningful improvements in the case group compared to the control group, particularly for the Total WOMAC score and the Pain sub-scale. These findings provide compelling evidence for the symptomatic benefit of lateral wedge insoles, directly addressing the question of clinical relevance. The following sections have been updated: • Methods: Added a description of the WOMAC data collection. • Results: Added a new subsection detailing the WOMAC results. • Discussion: Integrated the interpretation of the WOMAC findings with the radiographic results. • Abstract and Conclusion: Updated to reflect the new clinical findings. We believe the inclusion of this data substantially strengthens our paper and we are grateful for the reviewer's guidance on this matter Is the study sufficiently powered? We acknowledge the reviewer's concern regarding statistical power. The final sample size was indeed smaller than initially planned due to participant dropout, a common challenge in longitudinal studies. A post-hoc power analysis confirmed that the study was underpowered to detect smaller effect sizes, particularly for the inter-limb differences observed. Therefore, the significant findings on the left limb should be interpreted with caution as preliminary evidence. We have revised the manuscript to explicitly state this limitation and to frame our conclusions as generating hypotheses for future research rather than providing definitive clinical guidance. We believe the novel within-subject, multiple-height design provides valuable data that can be used to inform sample size calculations for larger, definitive trials. In the results: Since a total number of 34 participants completed the study from the original 44 recruits, it should be noted that the final sample size may have limited the statistical power to detect smaller effect sizes, particularly in the side-specific analyses. In limitation: this was addressed. The post-hoc explanation for limb dominance is speculative We thank the reviewer for this comment, which allows us to clarify an important point. Limb dominance was indeed assessed during the study. As previously stated in the Discussion: "In the current study (where the right leg was predominantly the dominant side)..." This statement was based on data collected from participants regarding their leg dominance (through direct questioning about their kicking leg or leg used to step up on a stair). We apologize that this methodological detail was not explicitly described in the Methods section, creating the impression that it was a purely post-hoc consideration. In response to the reviewer's feedback, we have now: 1. Added a sentence to the Methods section under 'Participant selection' to clearly state that limb dominance was recorded (added to table 1 as well). 2. Refined the language in the Discussion to more carefully frame our interpretation of these results as a possible hypothesis derived from the observed dominance data, acknowledging that other unmeasured factors could also contribute to the differences. We believe these revisions provide greater methodological transparency and strengthen the interpretation of our findings Reviewer 2 Points 1 & 2 (Unclear Mechanism & Missing Context) We sincerely thank the reviewer for this exceptionally insightful critique that pushes us to refine the theoretical framework of our findings. We agree that the logical chain from phenomenon to mechanism to application needed greater clarity and depth. We have now substantially revised the Discussion to address this by: 1. Providing the Missing Contextual Basis: We have amended the text to establish the foundational, well-accepted context that was previously implied (discussion is amended now and highlighted). 2. Defining the Specific Mechanistic Pathway: The reviewer correctly noted that the pathway from "mechanical stress" to "compromised LWI effectiveness" was vague. We have now elaborated on a reasonable, step-by-step biomechanical and structural pathway: • Step 1 (Chronic Stress): The dominant limb is subject to greater cumulative mechanical stress over a lifetime. • Step 2 (Structural Adaptation): This chronic stress can accelerate joint degeneration and lead to more established structural adaptations in medial knee OA (e.g., greater cartilage wear, bone remodeling, ligamentous laxity). We link this to the cited literature on dominant limb pathology [29]. • Step 3 (Biomechanical Stiffness): These structural changes may result in a biomechanically "stiffer" or less responsive joint. The joint's alignment may be more fixed, and the soft tissues less capable of facilitating the postural adjustments induced by the LWI. • Step 4 (Impact on LWI Mechanism): The primary mechanism of a LWI is to cause subtle foot pronation, thereby shifting the ground reaction force and reducing the external knee adduction moment (EKAM). We hypothesize that a more degenerated and structurally adapted dominant limb has a diminished capacity to translate the LWI's foot-level correction into a meaningful knee-level realignment. The higher baseline stress and altered joint mechanics may effectively "overwhelm" the intervention's biomechanical effect. This elaborated pathway moves from a general observation to a specific hypothesis about why our radiographic outcomes (FTA, MJSW) showed a weaker response on the dominant side. Table Optimization Directions 1. Table 1 Improvement: Adopt the three-line table format mandated by clinical research standards, clearly distinguishing headers, data columns, and footers. Additionally, incorporate gender and age as critical confounding factors during data analysis. Employ stratified analysis and multivariate regression to eliminate their interference, ensuring result accuracy. We thank the reviewer for this critical suggestion to enhance the clarity and statistical thoroughness of our baseline data presentation. We have fully implemented both recommendations as follows: 1. Three-Line Table Format: Table 1 has been reformatted into the mandated three-line table format, removing all vertical and unnecessary horizontal lines for a cleaner and more professional presentation. 2. Also, as requested, we have now formally compared the baseline characteristics of the control and case groups. We have added a new column to Table 1 displaying the p-values from independent samples t-tests (for age, BMI, weight, height) and tests for gender and dominince. The results confirm that there were no statistically significant differences between the groups for any of these variables at baseline (p > 0.05). Regarding the use of stratified analysis or multivariate regression to control for these factors in the outcome analysis: our primary statistical test, the Mixed ANOVA, is a robust model that inherently accounts for within-subject variability and compares the change over time between groups. Given that the groups were demonstrably equivalent at baseline (as now proven in the revised Table 1), the significant interaction effects (group*time) we report are unlikely to be driven by confounding from age or gender. However, we acknowledge the reviewer's point and have added a sentence to the statistical analysis section and the limitations to reflect this consideration. 2. Table 2 Improvement: Similarly, adhere to the three-line table format and supplement with tests or adjustments for baseline characteristic balance (e.g., gender, age). If other potential confounders exist (e.g., disease duration, comorbidities), incorporate them into the control scope to avoid compromising the reliability of conclusions. We thank the reviewer for this suggestion to enhance the clarity and strength of our results table. 1. Three-Line Table Format: We have reformatted Table 2 into the required three-line table format for improved clarity and presentation. 2. 3. Addressing Baseline Balance and Confounders: We agree that ensuring results are not confounded by baseline differences is paramount. We would like to clarify the properties of our chosen statistical model, the Mixed ANOVA: o This model is specifically designed for longitudinal data and inherently uses each subject's own baseline value as the reference point. The significant "group*time" interaction effect we report directly tests whether the pattern of change over time is different between the groups, already controlling for the starting point. o Furthermore, as now demonstrated in the revised Table 1, the groups were well-balanced on all measured baseline characteristics (age, gender, BMI, dominance), making it unlikely that these factors are driving the observed effects. Regarding the control of other potential confounders such as disease duration or comorbidities, we acknowledge this as a valuable point. We have added a statement to the Limitations section to this effect. We agree that future studies with larger sample sizes should prospectively collect and control for these variables using multivariate models. Enhancing the Clinical Argumentation Loop The logical framework of clinical research must form a complete loop: “Data Support → Clinical Validation → Patient Benefit.” “Clinical image comparisons” serve as the core bridge linking ‘data’ to “patient benefit.” The original text only addresses “multi-height data comparisons under standardized conditions,” achieving laboratory-level variable control but failing to provide critical clinical support through actual images: • Supplement with pre- and post-intervention joint imaging (e.g., X-ray, MRI) to visually demonstrate structural benefits like joint space widening and osteophyte reduction. • Incorporate functional assessment images (e.g., gait analysis diagrams, pain VAS trend charts) to demonstrate how data differences translate into tangible clinical outcomes like “reduced joint pain” and “enhanced walking ability.” Without such visual validation, the conclusion that “LWI studies show superiority” lacks the critical link between laboratory data and real patient benefits, failing to form a complete clinical evidence loop. We thank the reviewer for this profound comment, which elevate the clinical narrative and impact of our work. We agree entirely that having a direct, visual link between biomechanical data and patient benefit is the cornerstone of impactful clinical research. We are pleased to inform the reviewer that we have directly addressed the core of this feedback through a major revision: 1. Inclusion of Patient-Reported Outcomes (Figure 4): In direct response to Reviewer #1's similar concern, we have now integrated the full results from the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) throughout the manuscript. In our initial submission, we focused exclusively on the radiographic outcomes (FTA and MJSW) to maintain a clear and concise narrative on the structural and biomechanical effects of different LWI heights. However, we did indeed collect PROs throughout the study using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). The data show significant improvements in total score and, most notably, the Pain sub-scale in the case group. We believe this inclusion is the most critical step in "closing the clinical loop," as the WOMAC score is a direct, validated measure of the patient's own experience of their symptoms and functional limitations. 2. Regarding the suggestion to include pre- and post-intervention X-rays, we agree that visual evidence is powerful. However, we wish to note that the changes in Medial Joint Space Width (MJSW), while statistically significant and clinically important in the context of disease progression, are subtle at the individual level. These changes are quantifiable by software but are often invisible to the human eye on a standard printed radiograph, and their presentation might therefore be misleading or unconvincing. Therefore, to address the reviewer's request for a "bridge" between data and benefit, we have taken a more strategic and impactful approach: We have created a new composite figure (Figure 6) that visually constructs the "clinical argumentation loop." This figure integrates our key radiographic endpoint (MJSW) with our patient-reported outcome (WOMAC Pain) data. It visually demonstrates the parallel trends of structural preservation (MJSW) and symptomatic improvement (WOMAC Pain) across the intervention period, thereby creating a direct link between the laboratory data and the patient benefit. We are confident that these revisions, the inclusion of the WOMAC data and the new synthesizing figure, powerfully close the clinical evidence loop and greatly enhance the translational message of our paper. Submitted filename: Table of responses.docx 2 Feb 2026 PONE-D-25-45930R1 The Impact of Insole Wedge Height on Knee Alignment, Joint Space Width, and Patient-Reported Outcomes in Medial Knee OA PLOS One Dear Dr. Al Qaroot, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we have decided that your manuscript does not meet our criteria for publication and must therefore be rejected. I am sorry that we cannot be more positive on this occasion, but hope that you appreciate the reasons for this decision. Kind regards, Osama Farouk Academic Editor PLOS One Additional Editor Comments: Ignoring the assessment of limb axis as a parameter for knee joint alignment, as well as potential pathology of segments of the lower limb adjacent to the knee joint, makes the current methodology of the study, as well as the results and conclusions, questionable and inaccurate. It is a fundamental issue in the methodology of the study. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author Reviewer #1: All comments have been addressed Reviewer #3: All comments have been addressed ********** 2. Is the manuscript technically sound, and do the data support the conclusions??> Reviewer #1: Yes Reviewer #3: No ********** 3. Has the statistical analysis been performed appropriately and rigorously? -->?> Reviewer #1: Yes Reviewer #3: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available??> The PLOS Data policy Reviewer #1: Yes Reviewer #3: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English??> Reviewer #1: Yes Reviewer #3: Yes ********** Reviewer #1: This is a well-conceived and methodologically sound randomized controlled trial (RCT) that addresses a clinically relevant question in the conservative management of knee osteoarthritis (OA). The study provides valuable evidence supporting the use of LWIs and makes a novel contribution by systematically comparing multiple wedge heights within the same patient cohort. The conclusions are generally supported by the data, though some interpretations warrant cautious consideration. Reviewer #3: Thanks to the authors for the work done and the feedback provided by patients on an interesting method of conservative treatment of OA. However, the conclusions that the authors formulate based on the analysis of only short X-rays (not even in the Rosenberg view), before and after conservative treatment, cast doubt on the meaning of publishing the manuscript based on the results of this study as a whole. It's not even about small groups, although of course a lot of research power would only enhance the work. Unfortunately, ignoring the limb axis as a whole, with appropriate analysis of multispiral computed tomography (as the "gold standard") or telerentgenography data, as well as the possible presence of extra-articular deformities in patients, as well as potential pathology of segments of the lower limb adjacent to the knee joint, makes the current methodology of the study, as well as the results and conclusions questionable and incorrect from the point of view of the principles of planning, evidence-based medicine and common sense in general. Perhaps in the future the paper will have great interest and potential for citation, but alas, the current research design and methods need a lot of revision. ********** what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy Reviewer #1: No Reviewer #3: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] - - - - - For journal use only: PONEDEC3 11 Feb 2026 Revision 1 Comment Response Reviewer 1 Why were patient-reported outcomes (PROs) not included? We thank the reviewer for this critical and insightful comment. We completely agree that patient-reported outcomes (PROs) are essential for evaluating the clinical relevance of interventions for knee OA. In our initial submission, we focused exclusively on the radiographic outcomes (FTA and MJSW) to maintain a clear and concise narrative on the structural and biomechanical effects of different LWI heights. However, we did indeed collect PROs throughout the study using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). In direct response to the reviewer's comment, we have now integrated the full WOMAC results into the manuscript. The data show significant and clinically meaningful improvements in the case group compared to the control group, particularly for the Total WOMAC score and the Pain sub-scale. These findings provide compelling evidence for the symptomatic benefit of lateral wedge insoles, directly addressing the question of clinical relevance. The following sections have been updated: • Methods: Added a description of the WOMAC data collection. • Results: Added a new subsection detailing the WOMAC results. • Discussion: Integrated the interpretation of the WOMAC findings with the radiographic results. • Abstract and Conclusion: Updated to reflect the new clinical findings. We believe the inclusion of this data substantially strengthens our paper and we are grateful for the reviewer's guidance on this matter Is the study sufficiently powered? We acknowledge the reviewer's concern regarding statistical power. The final sample size was indeed smaller than initially planned due to participant dropout, a common challenge in longitudinal studies. A post-hoc power analysis confirmed that the study was underpowered to detect smaller effect sizes, particularly for the inter-limb differences observed. Therefore, the significant findings on the left limb should be interpreted with caution as preliminary evidence. We have revised the manuscript to explicitly state this limitation and to frame our conclusions as generating hypotheses for future research rather than providing definitive clinical guidance. We believe the novel within-subject, multiple-height design provides valuable data that can be used to inform sample size calculations for larger, definitive trials. In the results: Since a total number of 34 participants completed the study from the original 44 recruits, it should be noted that the final sample size may have limited the statistical power to detect smaller effect sizes, particularly in the side-specific analyses. In limitation: this was addressed. The post-hoc explanation for limb dominance is speculative We thank the reviewer for this comment, which allows us to clarify an important point. Limb dominance was indeed assessed during the study. As previously stated in the Discussion: "In the current study (where the right leg was predominantly the dominant side)..." This statement was based on data collected from participants regarding their leg dominance (through direct questioning about their kicking leg or leg used to step up on a stair). We apologize that this methodological detail was not explicitly described in the Methods section, creating the impression that it was a purely post-hoc consideration. In response to the reviewer's feedback, we have now: 1. Added a sentence to the Methods section under 'Participant selection' to clearly state that limb dominance was recorded (added to table 1 as well). 2. Refined the language in the Discussion to more carefully frame our interpretation of these results as a possible hypothesis derived from the observed dominance data, acknowledging that other unmeasured factors could also contribute to the differences. We believe these revisions provide greater methodological transparency and strengthen the interpretation of our findings Reviewer 2 Points 1 & 2 (Unclear Mechanism & Missing Context) We sincerely thank the reviewer for this exceptionally insightful critique that pushes us to refine the theoretical framework of our findings. We agree that the logical chain from phenomenon to mechanism to application needed greater clarity and depth. We have now substantially revised the Discussion to address this by: 1. Providing the Missing Contextual Basis: We have amended the text to establish the foundational, well-accepted context that was previously implied (discussion is amended now and highlighted). 2. Defining the Specific Mechanistic Pathway: The reviewer correctly noted that the pathway from "mechanical stress" to "compromised LWI effectiveness" was vague. We have now elaborated on a reasonable, step-by-step biomechanical and structural pathway: • Step 1 (Chronic Stress): The dominant limb is subject to greater cumulative mechanical stress over a lifetime. • Step 2 (Structural Adaptation): This chronic stress can accelerate joint degeneration and lead to more established structural adaptations in medial knee OA (e.g., greater cartilage wear, bone remodeling, ligamentous laxity). We link this to the cited literature on dominant limb pathology [29]. • Step 3 (Biomechanical Stiffness): These structural changes may result in a biomechanically "stiffer" or less responsive joint. The joint's alignment may be more fixed, and the soft tissues less capable of facilitating the postural adjustments induced by the LWI. • Step 4 (Impact on LWI Mechanism): The primary mechanism of a LWI is to cause subtle foot pronation, thereby shifting the ground reaction force and reducing the external knee adduction moment (EKAM). We hypothesize that a more degenerated and structurally adapted dominant limb has a diminished capacity to translate the LWI's foot-level correction into a meaningful knee-level realignment. The higher baseline stress and altered joint mechanics may effectively "overwhelm" the intervention's biomechanical effect. This elaborated pathway moves from a general observation to a specific hypothesis about why our radiographic outcomes (FTA, MJSW) showed a weaker response on the dominant side. Table Optimization Directions 1. Table 1 Improvement: Adopt the three-line table format mandated by clinical research standards, clearly distinguishing headers, data columns, and footers. Additionally, incorporate gender and age as critical confounding factors during data analysis. Employ stratified analysis and multivariate regression to eliminate their interference, ensuring result accuracy. We thank the reviewer for this critical suggestion to enhance the clarity and statistical thoroughness of our baseline data presentation. We have fully implemented both recommendations as follows: 1. Three-Line Table Format: Table 1 has been reformatted into the mandated three-line table format, removing all vertical and unnecessary horizontal lines for a cleaner and more professional presentation. 2. Also, as requested, we have now formally compared the baseline characteristics of the control and case groups. We have added a new column to Table 1 displaying the p-values from independent samples t-tests (for age, BMI, weight, height) and tests for gender and dominince. The results confirm that there were no statistically significant differences between the groups for any of these variables at baseline (p > 0.05). Regarding the use of stratified analysis or multivariate regression to control for these factors in the outcome analysis: our primary statistical test, the Mixed ANOVA, is a robust model that inherently accounts for within-subject variability and compares the change over time between groups. Given that the groups were demonstrably equivalent at baseline (as now proven in the revised Table 1), the significant interaction effects (group*time) we report are unlikely to be driven by confounding from age or gender. However, we acknowledge the reviewer's point and have added a sentence to the statistical analysis section and the limitations to reflect this consideration. 2. Table 2 Improvement: Similarly, adhere to the three-line table format and supplement with tests or adjustments for baseline characteristic balance (e.g., gender, age). If other potential confounders exist (e.g., disease duration, comorbidities), incorporate them into the control scope to avoid compromising the reliability of conclusions. We thank the reviewer for this suggestion to enhance the clarity and strength of our results table. 1. Three-Line Table Format: We have reformatted Table 2 into the required three-line table format for improved clarity and presentation. 2. 3. Addressing Baseline Balance and Confounders: We agree that ensuring results are not confounded by baseline differences is paramount. We would like to clarify the properties of our chosen statistical model, the Mixed ANOVA: o This model is specifically designed for longitudinal data and inherently uses each subject's own baseline value as the reference point. The significant "group*time" interaction effect we report directly tests whether the pattern of change over time is different between the groups, already controlling for the starting point. o Furthermore, as now demonstrated in the revised Table 1, the groups were well-balanced on all measured baseline characteristics (age, gender, BMI, dominance), making it unlikely that these factors are driving the observed effects. Regarding the control of other potential confounders such as disease duration or comorbidities, we acknowledge this as a valuable point. We have added a statement to the Limitations section to this effect. We agree that future studies with larger sample sizes should prospectively collect and control for these variables using multivariate models. Enhancing the Clinical Argumentation Loop The logical framework of clinical research must form a complete loop: “Data Support → Clinical Validation → Patient Benefit.” “Clinical image comparisons” serve as the core bridge linking ‘data’ to “patient benefit.” The original text only addresses “multi-height data comparisons under standardized conditions,” achieving laboratory-level variable control but failing to provide critical clinical support through actual images: • Supplement with pre- and post-intervention joint imaging (e.g., X-ray, MRI) to visually demonstrate structural benefits like joint space widening and osteophyte reduction. • Incorporate functional assessment images (e.g., gait analysis diagrams, pain VAS trend charts) to demonstrate how data differences translate into tangible clinical outcomes like “reduced joint pain” and “enhanced walking ability.” Without such visual validation, the conclusion that “LWI studies show superiority” lacks the critical link between laboratory data and real patient benefits, failing to form a complete clinical evidence loop. We thank the reviewer for this profound comment, which elevate the clinical narrative and impact of our work. We agree entirely that having a direct, visual link between biomechanical data and patient benefit is the cornerstone of impactful clinical research. We are pleased to inform the reviewer that we have directly addressed the core of this feedback through a major revision: 1. Inclusion of Patient-Reported Outcomes (Figure 4): In direct response to Reviewer #1's similar concern, we have now integrated the full results from the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) throughout the manuscript. In our initial submission, we focused exclusively on the radiographic outcomes (FTA and MJSW) to maintain a clear and concise narrative on the structural and biomechanical effects of different LWI heights. However, we did indeed collect PROs throughout the study using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). The data show significant improvements in total score and, most notably, the Pain sub-scale in the case group. We believe this inclusion is the most critical step in "closing the clinical loop," as the WOMAC score is a direct, validated measure of the patient's own experience of their symptoms and functional limitations. 2. Regarding the suggestion to include pre- and post-intervention X-rays, we agree that visual evidence is powerful. However, we wish to note that the changes in Medial Joint Space Width (MJSW), while statistically significant and clinically important in the context of disease progression, are subtle at the individual level. These changes are quantifiable by software but are often invisible to the human eye on a standard printed radiograph, and their presentation might therefore be misleading or unconvincing. Therefore, to address the reviewer's request for a "bridge" between data and benefit, we have taken a more strategic and impactful approach: We have created a new composite figure (Figure 6) that visually constructs the "clinical argumentation loop." This figure integrates our key radiographic endpoint (MJSW) with our patient-reported outcome (WOMAC Pain) data. It visually demonstrates the parallel trends of structural preservation (MJSW) and symptomatic improvement (WOMAC Pain) across the intervention period, thereby creating a direct link between the laboratory data and the patient benefit. We are confident that these revisions, the inclusion of the WOMAC data and the new synthesizing figure, powerfully close the clinical evidence loop and greatly enhance the translational message of our paper. Revision 2 Comment Response Academic Editor Comment Ignoring assessment of limb axis and adjacent segment pathology makes the methodology, results, and conclusions questionable and inaccurate. The study was intentionally designed to evaluate knee-level structural outcomes relevant to conservative orthotic management femerotibial angle (FTA) and medial joint space width (MJSW) using short, weight-bearing knee radiographs, a validated and widely used approach in conservative knee OA trials. The manuscript does not claim assessment or correction of whole-limb mechanical axis, nor does it draw conclusions beyond knee-level alignment and joint space behavior. Whole-limb imaging was not requested during the initial review round and was not part of the revision request. Introducing this requirement at the post-revision stage represents a change in scope rather than identification of a technical flaw. To avoid ambiguity, we have strengthened the Methods, Discussion, and Limitations sections to explicitly acknowledge the absence of full-limb axis assessment and to state that future studies should incorporate full-length imaging to evaluate global biomechanical effects. Reviewer 2 Use of short X-rays without whole-limb axis assessment renders the study design and conclusions questionable. The concern reflects a preference for an alternative study design rather than a failure of technical validity. Short, weight-bearing knee radiographs are an accepted and validated method for assessing FTA and MJSW in conservative OA research and are appropriate for the stated research question. The conclusions are explicitly limited to knee-level structural and symptomatic outcomes and do not extrapolate to global limb alignment or extra-articular deformity. These limitations are now stated more explicitly in the manuscript. The issue raised does not invalidate the data, analysis, or conclusions within the defined scope of the study. 25 Jun 2026 Dear Dr. Al Qaroot, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Aug 09 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. As the corresponding author, your ORCID iD is verified in the submission system and will appear in the published article. PLOS supports the use of ORCID, and we encourage all coauthors to register for an ORCID iD and use it as well. Please encourage your coauthors to verify their ORCID iD within the submission system before final acceptance, as unverified ORCID iDs will not appear in the published article. Only the individual author can complete the verification step; PLOS staff cannot verify ORCID iDs on behalf of authors. We look forward to receiving your revised manuscript. Kind regards, Rohan Kothurkar, PhD Academic Editor PLOS One Journal Requirements: If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. Additional Editor Comments (if provided): [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author Reviewer #1: All comments have been addressed Reviewer #4: All comments have been addressed Reviewer #5: All comments have been addressed ********** 2. Is the manuscript technically sound, and do the data support the conclusions??> Reviewer #1: Partly Reviewer #4: Yes Reviewer #5: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously? -->?> Reviewer #1: Yes Reviewer #4: Yes Reviewer #5: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available??> The PLOS Data policy Reviewer #1: Yes Reviewer #4: Yes Reviewer #5: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English??> Reviewer #1: Yes Reviewer #4: Yes Reviewer #5: Yes ********** Reviewer #1: Critical discrepancy between study design and reporting: The abstract and title describe a randomized controlled trial with a case group and a control group, yet the Methods clearly indicate that the case group received four different insole heights sequentially (4, 8, 12, and 16 mm) over time, which constitutes a within-subjects repeated-measures design—not a parallel-group RCT. Could you please clarify whether the control group underwent the same repeated follow-up schedule without any insole, and if so, how the “group×time” interaction can be interpreted as a true between-group comparison when the case group’s time points represent different interventions rather than a single, constant treatment? Interpretation of side-specific effects: The significant FTA improvement was observed only on the left (non-dominant) side, not on the right (dominant) side. Given that the majority of participants were right-leg dominant, the authors hypothesize that chronic loading on the dominant limb may have led to more “fixed” degenerative changes. If the insole is biomechanically effective, why would it not produce at least a measurable kinematic shift on the dominant side within the 4-week period? Does this asymmetry not undermine the generalizability of the conclusion that “12mm LWI significantly reduces varus alignment,” when this effect appears to be side-dependent and only statistically detectable in the non-dominant limb? Exclusion of the 16mm data and optimal height claim: The 16mm condition was discontinued due to poor tolerability (11/17 participants) and excluded from analysis. How can the conclusion that “12mm is particularly effective” be justified when the higher dose (16mm) was not fully tested? Was any attempt made to analyze the available data from those who did tolerate the 16mm insole, and how do the authors account for the potential selection bias introduced by excluding nearly two-thirds of the case group at that height? Sample size and power: With an initial recruitment of 44 and a final sample of 34, the authors acknowledge limited power. Could you provide a post-hoc power analysis for the primary outcome (FTA/MJSW) to confirm whether the null findings on the dominant side and for stiffness/physical function subscales are indeed due to a lack of effect or insufficient sample size? Long-term relevance of radiographic outcomes: While the 4-week intervention shows stabilization of MJSW in the case group versus narrowing in controls, do the authors plan to conduct a longer-term follow-up (e.g., 6–12 months) to assess whether this structural preservation translates into sustained clinical benefit and delayed disease progression, especially given that the WOMAC improvements were also observed? Reviewer #4: I congratulate you on this study and work . Hope you can come ahead with a larger cohort as well in the near future. Reviewer #5: The study addresses a clinically relevant topic and suggests that a 12-mm lateral wedge insole may provide the best balance between biomechanical effectiveness and tolerability. However, important methodological clarifications, stronger statistical reporting, improved transparency, and more cautious interpretation of findings are required before the manuscript can be considered for publication. Expand the discussion of previous literature and explain how the present findings differ from existing evidence on lateral wedge insoles. Discuss the potential impact of BMI, physical activity level, occupation, and medication use as confounding factors. Consider adding a limitations paragraph regarding short follow-up duration and lack of functional outcomes. ********** what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy Reviewer #1: Yes: Chunlin Yang Reviewer #4: Yes: Sushant Srivastava Reviewer #5: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation. NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications. 26 Jun 2026 Reviewer #1: Comment 1: Critical discrepancy between study design and reporting: The abstract and title describe a randomized controlled trial with a case group and a control group, yet the Methods clearly indicate that the case group received four different insole heights sequentially (4, 8, 12, and 16 mm) over time, which constitutes a within-subjects repeated-measures design—not a parallel-group RCT. Could you please clarify whether the control group underwent the same repeated follow-up schedule without any insole, and if so, how the “group×time” interaction can be interpreted as a true between-group comparison when the case group’s time points represent different interventions rather than a single, constant treatment? Response: We sincerely thank the reviewer for this critical observation. The reviewer is entirely correct. We acknowledge that our design is not a conventional parallel-group RCT where both groups receive a single, fixed intervention across the entire follow-up period. To clarify: Yes, the control group underwent the exact same repeated follow-up schedule (at baseline, 4 weeks, 8 weeks, and 12 weeks) without any insole intervention to serve as a natural history comparator for disease progression. We have now substantially revised the description of our design throughout the manuscript to accurately reflect its true nature: a combined design featuring (1) a parallel-group, untreated control arm to track natural history, and (2) a sequential, within-subject dose-escalation intervention arm (testing 4mm, 8mm, and 12mm LWIs) to evaluate the dose-response relationship. Regarding the interpretation of the "group×time" interaction: We agree with the reviewer that the "time" factor is confounded with "intervention dose" in the case group. Therefore, we do not interpret this interaction as a simple chronological time effect. Instead, we interpret it as evidence that the dose-dependent trajectory of changes observed in the case group (i.e., progressive biomechanical and symptomatic improvement as the wedge height increased from 4mm to 12mm) deviates significantly from the trajectory of natural progression observed in the control group. To provide a robust parallel-group comparison, we have now added explicit supplementary analyses comparing the control group directly to the case group at the final 12mm endpoint (which acts as a true between-group comparison at a single time point), further confirming the superiority of the active intervention over standard care. We have revised the Abstract, Methods, discussion, statistical Analysis, and limitations sections below to eliminate this ambiguity and ensure readers clearly understand the unique value of this hybrid design. Comment 2: Interpretation of side-specific effects: The significant FTA improvement was observed only on the left (non-dominant) side, not on the right (dominant) side. Given that the majority of participants were right-leg dominant, the authors hypothesize that chronic loading on the dominant limb may have led to more “fixed” degenerative changes. If the insole is biomechanically effective, why would it not produce at least a measurable kinematic shift on the dominant side within the 4-week period? Does this asymmetry not undermine the generalizability of the conclusion that “12mm LWI significantly reduces varus alignment,” when this effect appears to be side-dependent and only statistically detectable in the non-dominant limb? Response: We thank the reviewer for this insightful and critical observation. We agree that the side-dependent nature of the FTA improvement requires careful interpretation and honest acknowledgment. 1. Why would the insole not produce a measurable kinematic shift on the dominant side within 4 weeks? We propose that the dominant limb's degenerative changes are more structurally advanced and potentially less amenable to acute biomechanical correction, even though radiographic grading (Kellgren-Lawrence) was matched between limbs. The key distinction is between radiographic severity and structural responsiveness: • Radiographic matching (Kellgren-Lawrence grade <3) ensured both limbs had comparable structural damage at baseline. • However, limb dominance is associated with asymmetric loading history over decades. The dominant limb experiences higher impact forces, greater propulsive demands, and more cumulative mechanical stress during gait and weight-bearing activities [Turkiewicz et al., 2015; Sadeghi et al., 2000]. • This chronic, elevated loading may lead to subtle but functionally significant differences in cartilage composition, subchondral bone stiffness, and periarticular soft tissue adaptation—changes not fully captured by Kellgren-Lawrence grading alone. • These adaptations could render the dominant limb biomechanically less responsive to acute correction. The LWI works by inducing foot pronation, which alters the kinematic chain up to the knee. If the dominant knee has more structurally fixed varus due to long-term asymmetric loading, the kinematic correction may be partially dampened before producing a measurable FTA shift within 4 weeks. In other words: The absence of a measurable shift on the dominant side does not mean the insole is ineffective; it may simply indicate that the dominant joint requires a longer intervention period or a more substantial mechanical stimulus to produce detectable structural change. 2. Does this asymmetry undermine the generalizability of the conclusion? Yes and no. We now phrase our conclusion more precisely: • Yes: We cannot generalize that "12mm LWI significantly reduces varus alignment" as a universal statement for all limbs. • No: We can conclude that in the non-dominant limb (which represents the joint less exposed to chronic asymmetric overloading) the 12mm LWI produces significant varus correction. This is clinically meaningful because: o The non-dominant limb still bears significant weight during gait and is susceptible to OA progression. o The finding suggests that earlier intervention (before asymmetric loading has caused more "fixed" changes) may be more effective. o It highlights that limb dominance is a clinically relevant factor that should be considered when prescribing LWIs and when designing future trials. We have revised our conclusion to state: "In this cohort, the 12mm LWI significantly reduced varus alignment in the non-dominant limb. The absence of a similar effect in the dominant limb suggests that limb-specific loading history may modulate biomechanical responsiveness, and that the generalizability of this finding is primarily applicable to joints without advanced asymmetric degenerative adaptation. This observation underscores the need for personalized prescription and further investigation into the role of limb dominance in orthotic efficacy." 3. Does this affect the clinical take-home message? No. The clinical significance of our findings is supported by: • Consistent improvements in patient-reported outcomes (WOMAC pain and total score) that were bilateral (not side-specific), indicating that symptom relief is not dependent on FTA correction alone. • Preserved MJSW bilaterally in the case group versus narrowing in controls; this structural preservation was seen on both sides, suggesting a disease-modifying effect independent of measurable FTA change. • The dose-response relationship (4mm → 8mm → 12mm) showing progressive improvement in the case group, which was not observed in controls. Thus, while the FTA effect is side-specific, the overall therapeutic benefit of the 12mm LWI is supported by multiple converging lines of evidence. Comment 3: Exclusion of the 16mm data and optimal height claim: The 16mm condition was discontinued due to poor tolerability (11/17 participants) and excluded from analysis. How can the conclusion that “12mm is particularly effective” be justified when the higher dose (16mm) was not fully tested? Was any attempt made to analyze the available data from those who did tolerate the 16mm insole, and how do the authors account for the potential selection bias introduced by excluding nearly two-thirds of the case group at that height? Response: We thank the reviewer for this important methodological critique. We acknowledge that the 16mm condition was not fully tested and that our conclusion requires more precise wording. 1. How can the conclusion that "12mm is particularly effective" be justified when the higher dose was not fully tested? We have revised our conclusion to be more precise. We do not claim that 12mm is the biomechanically optimal height—we cannot know this because 16mm was not fully tested. Instead, we conclude that 12mm is the most effective height among those that were clinically tolerable and feasible for sustained use. In other words: 12mm represents the best balance between biomechanical efficacy and patient tolerability within the tested range. This is a clinically meaningful conclusion because an intervention that patients cannot tolerate has zero real-world effectiveness, regardless of its theoretical biomechanical potential. 2. Was any attempt made to analyze the available data from those who did tolerate the 16mm insole? Yes. We performed an exploratory analysis of the 6 participants who tolerated the 16mm LWI. Their data showed a trend toward further FTA improvement compared to 12mm (mean difference = -0.6°, p = 0.18), but this was not statistically significant due to the very small sample size (n=6). We have now added this as supplementary information (see below). 3. How do we account for the potential selection bias? We acknowledge this limitation explicitly. The 6 participants who tolerated 16mm may represent a subset with different biomechanical characteristics (e.g., greater baseline joint laxity, less severe OA, different foot morphology, or higher pain tolerance). Therefore, any findings from the 16mm condition are not generalizable to the broader patient population. We have added this to our limitations section. However, the high dropout rate itself is a clinically significant finding: 11 out of 17 participants could not tolerate the 16mm LWI. This is not a failure of the study—it is a clinically relevant result that informs prescription practice. It demonstrates that 16mm is impractical for routine clinical use, regardless of its theoretical efficacy. We have amended the article to account for this comment. Comment 4: Sample size and power: With an initial recruitment of 44 and a final sample of 34, the authors acknowledge limited power. Could you provide a post-hoc power analysis for the primary outcome (FTA/MJSW) to confirm whether the null findings on the dominant side and for stiffness/physical function subscales are indeed due to a lack of effect or insufficient sample size? Response: We thank the reviewer for this important methodological question. We have now performed post-hoc power analyses for our primary outcomes to clarify the interpretation of our null findings. 1. Post-hoc power analysis for primary outcomes (FTA and MJSW): Based on our observed effect sizes, the achieved power for the primary analyses was as follows: Outcome Effect Size (partial η²) Observed Power FTA (left side) – group×time interaction 0.053 0.82 FTA (right side) – group×time interaction 0.001 0.06 MJSW (left side) – group×time interaction 0.032 0.61 MJSW (right side) – group×time interaction 0.009 0.15 These analyses confirm that: • The significant FTA effect on the left (non-dominant) side was adequately powered (observed power = 0.82), supporting the validity of this finding. • The null FTA finding on the right (dominant) side is associated with very low observed power (0.06), meaning we cannot confidently conclude that no effect exists. The absence of a significant effect on the dominant side may indeed reflect insufficient power to detect a smaller effect size, rather than a true lack of biomechanical efficacy. • The MJSW findings (significant interaction on the left side, null on the right side) showed moderate power (0.61) on the left and very low power (0.15) on the right, suggesting the right-side null finding may also be influenced by limited sample size. • For the WOMAC stiffness and physical function subscales, which showed no significant interaction effects, the observed power ranged from 0.28 to 0.42, indicating insufficient power to detect small-to-moderate effects. This suggests that the null findings for these subscales may reflect inadequate sample size rather than a true absence of treatment benefit. 2. Are the null findings due to lack of effect or insufficient sample size? Based on the post-hoc power analysis, we cannot definitively distinguish between true absence of effect and insufficient power for several outcomes. Specifically: • Dominant side FTA: Likely underpowered; the null finding should not be interpreted as evidence that LWI has no effect on the dominant limb. • Stiffness and physical function subscales: Underpowered; these null findings should be interpreted cautiously. • Dominant side MJSW: Underpowered; the null finding is inconclusive. We have revised our manuscript to reflect this interpretation. We now state that the null findings on the dominant side and for certain WOMAC subscales may be attributable to limited statistical power, and we explicitly recommend larger sample sizes in future studies. 3. Should we include the post-hoc power analysis in the manuscript? Yes. We have added a brief summary of the post-hoc power analysis to the Statistical Analysis section and a more detailed presentation in the Limitations section. We have amended the results, discussion, conclusion, and limitation to account for this comment. Comment 5: Long-term relevance of radiographic outcomes: While the 4-week intervention shows stabilization of MJSW in the case group versus narrowing in controls, do the authors plan to conduct a longer-term follow-up (e.g., 6–12 months) to assess whether this structural preservation translates into sustained clinical benefit and delayed disease progression, especially given that the WOMAC improvements were also observed? Response: We thank the reviewer for this important question regarding the long-term clinical relevance of our findings. 1. Do we plan to conduct a longer-term follow-up? We fully agree that long-term follow-up is essential to determine whether the observed structural preservation translates into sustained clinical benefit and delayed disease progression. While our current study was not designed or funded for extended follow-up, we are actively planning a larger prospective cohort study with 12-month follow-up to address this question. In that study, we aim to include dynamic gait analysis and MRI-based cartilage assessment to provide more comprehensive evidence. 2. Does the absence of long-term follow-up undermine the current findings? No. We believe the current findings are clinically meaningful for the following reasons: • The 4-week intervention period is consistent with previous LWI studies that have demonstrated biomechanical and symptomatic effects within this timeframe [Kakihana et al., 2005; Toda et al., 2004; Hinman et al., 2012]. This duration is sufficient to detect acute structural and symptomatic responses. • The stabilization of MJSW in the case group versus progressive narrowing in the control group within 4 weeks is clinically significant because it suggests that the LWI may decelerate the natural progression of joint space narrowing—a key radiographic marker of OA progression [Reijman et al., 2005]. • The concordant improvements in WOMAC scores (pain and total) provide concurrent patient-reported evidence that the structural preservation is accompanied by tangible clinical benefit. However, we acknowledge that the 4-week timeframe does not allow us to conclude whether these effects are sustained beyond the intervention period. We have revised the manuscript to clearly state this limitation and to emphasize the need for long-term follow-up studies. We have, thus, amended the discussion, conclusion, and limitation to account for this comment. Reviewer 4 I congratulate you on this study and work . Hope you can come ahead with a larger cohort as well in Submitted filename: Table_of_responses_auresp_3.docx 8 Jul 2026 The Impact of Insole Wedge Height on Knee Alignment, Joint Space Width, and Patient-Reported Outcomes in Medial Knee OA PONE-D-25-45930R3 Dear Dr. Al Qaroot, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. For questions related to billing, please contact billing support. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Rohan Kothurkar, PhD Academic Editor PLOS One Additional Editor Comments (optional): Reviewers' comments: PONE-D-25-45930R3 PLOS One Dear Dr. Al Qaroot, I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS One. Congratulations! Your manuscript is now being handed over to our production team. At this stage, our production department will prepare your paper for publication. This includes ensuring the following: * All references, tables, and figures are properly cited * All relevant supporting information is included in the manuscript submission, * There are no issues that prevent the paper from being properly typeset You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps. Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. You will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing. If we can help with anything else, please email us at customercare@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Rohan Kothurkar Academic Editor PLOS One